Document is current
Any future updates will be listed below
-
Authors
Hauck, J. Spencer https://orcid.org/0000-0003-1722-8709
Moon, David
Jiang, Xue
Wang, Mu-En
Zhao, Yue
Xu, Lingfan
Quang, Holly https://orcid.org/0009-0008-4259-6718
Butler, William
Chen, Ming https://orcid.org/0000-0002-3470-1062
Macias, Everardo
Gao, Xia https://orcid.org/0000-0003-0979-9990
He, Yiping
Huang, Jiaoti https://orcid.org/0000-0003-1195-1998
-
Funding
Funding for this research was provided by:
Duke | Duke University School of Medicine | Duke Clinical Research Institute
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (PC200042)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (CA237618)
Cancer Prevention and Research Institute of Texas (PR210056)
- License Information
-
More Information
Article History
Received: 7 July 2023
Accepted: 19 December 2023
First Online: 3 January 2024
Competing interests
: J.H. is a consultant for or owns shares in the following companies: Amgen, Artera, Kingmed Diagnostics, MoreHealth, OptraScan, York Biotechnology, Genecode, Seagen Inc. and Sisu Pharma, and received grants from Zenith Epigenetics, BioXcel Therapeutics, Inc., Dracen Pharmaceuticals and Fortis Therapeutics. All other authors declare no competing interests’.
